OA12121A - Matrix tablet for prolonged release of trimetazidine after oral administration. - Google Patents
Matrix tablet for prolonged release of trimetazidine after oral administration. Download PDFInfo
- Publication number
- OA12121A OA12121A OA1200200181A OA1200200181A OA12121A OA 12121 A OA12121 A OA 12121A OA 1200200181 A OA1200200181 A OA 1200200181A OA 1200200181 A OA1200200181 A OA 1200200181A OA 12121 A OA12121 A OA 12121A
- Authority
- OA
- OAPI
- Prior art keywords
- matrix tablet
- tablet according
- trimetazidine
- matrix
- total mass
- Prior art date
Links
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960001177 trimetazidine Drugs 0.000 title claims abstract description 26
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 8
- 239000013563 matrix tablet Substances 0.000 title claims description 24
- 229920002678 cellulose Polymers 0.000 claims abstract description 11
- 239000001913 cellulose Substances 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 9
- 230000036470 plasma concentration Effects 0.000 claims description 9
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 7
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9915960A FR2802424B1 (fr) | 1999-12-17 | 1999-12-17 | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12121A true OA12121A (en) | 2003-10-20 |
Family
ID=9553398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200200181A OA12121A (en) | 1999-12-17 | 2000-12-15 | Matrix tablet for prolonged release of trimetazidine after oral administration. |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1108424B2 (en]) |
| JP (2) | JP2001172181A (en]) |
| KR (1) | KR100456933B1 (en]) |
| CN (1) | CN1166408C (en]) |
| AR (1) | AR026968A1 (en]) |
| AT (1) | ATE296622T1 (en]) |
| AU (1) | AU780011B2 (en]) |
| BG (1) | BG65773B1 (en]) |
| BR (1) | BR0005915A (en]) |
| CY (1) | CY2347B1 (en]) |
| CZ (1) | CZ299461B6 (en]) |
| DE (1) | DE60020501T3 (en]) |
| DK (1) | DK1108424T4 (en]) |
| EA (2) | EA008223B1 (en]) |
| ES (2) | ES2176106B1 (en]) |
| FR (1) | FR2802424B1 (en]) |
| GE (1) | GEP20053540B (en]) |
| GR (1) | GR1003658B (en]) |
| HU (1) | HU226956B1 (en]) |
| IE (1) | IE20001017A1 (en]) |
| IT (1) | IT1317075B1 (en]) |
| LU (1) | LU90700B1 (en]) |
| MX (1) | MXPA00012462A (en]) |
| NZ (1) | NZ508912A (en]) |
| OA (1) | OA12121A (en]) |
| PL (1) | PL206994B1 (en]) |
| PT (2) | PT1108424E (en]) |
| SI (1) | SI1108424T2 (en]) |
| SK (1) | SK286752B6 (en]) |
| UA (1) | UA80087C2 (en]) |
| WO (1) | WO2001043747A1 (en]) |
| ZA (1) | ZA200007548B (en]) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1195160E (pt) * | 2000-10-05 | 2009-12-07 | Usv Ltd | Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação |
| CN1842333A (zh) * | 2003-08-04 | 2006-10-04 | 杏林制药株式会社 | 口服缓释片剂 |
| SG126792A1 (en) * | 2005-04-27 | 2006-11-29 | Servier Lab | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
| FR2885807B1 (fr) * | 2005-05-18 | 2008-05-16 | Mg Pharma | Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation |
| UA12297U (en) * | 2005-11-24 | 2006-01-16 | Pharma Start Ltd Liability Com | Matrix tablet providing for delayed release of trimetasin |
| CZ300307B6 (cs) * | 2006-01-04 | 2009-04-15 | Zentiva, A. S. | Tableta s obsahem trimetazidinu nebo jeho farmakologicky akceptovatelné soli s modifikovaným uvolnováním |
| EA009776B1 (ru) * | 2006-07-18 | 2008-04-28 | Мераб Ревазович Кокеладзе | Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав |
| EA009810B1 (ru) * | 2006-12-26 | 2008-04-28 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Матрица для изготовления таблетированной лекарственной формы и способ лечения |
| WO2009034541A2 (en) * | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical dosage forms of trimetazidine |
| RU2362548C1 (ru) * | 2007-11-20 | 2009-07-27 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения |
| RU2377989C2 (ru) * | 2007-11-27 | 2010-01-10 | Товарыство з обмэжэною видповидальнистю "Фарма Старт" | Лекарственное средство триметазидина в форме матриксной таблетки с пролонгированным действием и способ его получения |
| WO2010084397A2 (en) | 2009-01-20 | 2010-07-29 | Micro Labs Limited | Modified release solid pharmaceutical compositions of trimetazidine and process thereof |
| HUE027498T2 (en) * | 2009-01-30 | 2016-10-28 | Lupin Ltd | Pharmaceutical preparations containing trimetazidine |
| TR201001902A2 (tr) | 2010-03-12 | 2011-04-21 | Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Uzatılmış salınımlı trimetazidin tablet |
| RU2445958C2 (ru) * | 2010-04-20 | 2012-03-27 | Общество с ограниченной ответственностью "Озон" (ООО "Озон") | Матричная таблетка с основой для пролонгированного высвобождения триметазидина и способ ее изготовления |
| ES2508490T3 (es) | 2010-05-04 | 2014-10-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Formulación de trimetazidina con diferentes perfiles de liberación |
| EP2386302A1 (en) | 2010-05-11 | 2011-11-16 | Ranbaxy Laboratories Limited | A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof |
| EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| FR2986431B1 (fr) * | 2012-02-03 | 2017-03-17 | Servier Lab | Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques |
| CN102824644B (zh) * | 2012-09-13 | 2013-12-25 | 浙江诚意药业有限公司 | 使用羟丙基纤维素制备的高稳定性的缓释片 |
| KR20160118733A (ko) | 2015-04-03 | 2016-10-12 | 이인현 | 호스 권취용 호스 안내장치 및 이를 구비한 호스 권취기 |
| CN109316455B (zh) * | 2017-07-31 | 2021-05-25 | 北京福元医药股份有限公司 | 一种盐酸曲美他嗪缓释片 |
| CN109908096A (zh) * | 2017-12-12 | 2019-06-21 | 武汉武药科技有限公司 | 一种盐酸曲美他嗪缓释片及其制备方法 |
| WO2024218267A2 (en) * | 2023-04-20 | 2024-10-24 | Les Laboratoires Servier | Novel trimetazidine solid phases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| FR2490963B1 (fr) * | 1980-09-30 | 1986-04-18 | Science Union & Cie | Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine |
| KR850006132A (ko) * | 1984-02-29 | 1985-10-02 | 진 크라메르, 한스 루돌프 하우스 | 브로모크립틴 조성물 |
| JPS61293931A (ja) * | 1985-06-24 | 1986-12-24 | Teijin Ltd | 徐放性医薬品組成物 |
| JPH0625055B2 (ja) * | 1985-03-18 | 1994-04-06 | 日本ケミフア株式会社 | 持続性錠剤 |
| DE3676235D1 (de) † | 1985-06-04 | 1991-01-31 | Teijin Ltd | Arzneizubereitung mit verzoegerter wirkstoffabgabe. |
| SE455836B (sv) * | 1985-10-11 | 1988-08-15 | Haessle Ab | Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning |
| SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
| FR2677886B1 (fr) * | 1991-06-18 | 1995-03-31 | Adir | Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale. |
| FR2681324B1 (fr) * | 1991-09-18 | 1993-10-29 | Adir Cie | Nouveaux derives de la trimetazidine, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| KR940021051A (ko) * | 1993-03-03 | 1994-10-17 | 손정삼 | 3단계 약물방출형 지속성 정제 |
| RU2082400C1 (ru) * | 1993-12-16 | 1997-06-27 | Акционерное общество - Фармацевтическая фирма "Ник-Фарм" | Способ получения нитроглицерина пролонгированного действия |
| FR2717687B1 (fr) * | 1994-03-24 | 1996-06-14 | Adir | Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale. |
-
1999
- 1999-12-17 FR FR9915960A patent/FR2802424B1/fr not_active Expired - Fee Related
-
2000
- 2000-12-11 JP JP2000375812A patent/JP2001172181A/ja active Pending
- 2000-12-14 AU AU72285/00A patent/AU780011B2/en not_active Expired
- 2000-12-14 CY CY0000059A patent/CY2347B1/xx unknown
- 2000-12-14 MX MXPA00012462A patent/MXPA00012462A/es active IP Right Grant
- 2000-12-14 IT IT2000RM000667A patent/IT1317075B1/it active
- 2000-12-15 DE DE60020501.0T patent/DE60020501T3/de not_active Expired - Lifetime
- 2000-12-15 NZ NZ508912A patent/NZ508912A/en not_active IP Right Cessation
- 2000-12-15 HU HU0004966A patent/HU226956B1/hu active IP Right Maintenance
- 2000-12-15 AR ARP000106662A patent/AR026968A1/es not_active Application Discontinuation
- 2000-12-15 OA OA1200200181A patent/OA12121A/en unknown
- 2000-12-15 GE GE4838A patent/GEP20053540B/en unknown
- 2000-12-15 PT PT00403533T patent/PT1108424E/pt unknown
- 2000-12-15 ES ES200003018A patent/ES2176106B1/es not_active Expired - Fee Related
- 2000-12-15 PT PT102542A patent/PT102542A/pt not_active IP Right Cessation
- 2000-12-15 PL PL344564A patent/PL206994B1/pl not_active IP Right Cessation
- 2000-12-15 LU LU90700A patent/LU90700B1/fr active
- 2000-12-15 SI SI200030704T patent/SI1108424T2/sl unknown
- 2000-12-15 DK DK00403533.3T patent/DK1108424T4/da active
- 2000-12-15 EP EP00403533.3A patent/EP1108424B2/fr not_active Expired - Lifetime
- 2000-12-15 CN CNB001380605A patent/CN1166408C/zh not_active Expired - Lifetime
- 2000-12-15 KR KR10-2000-0076962A patent/KR100456933B1/ko not_active Ceased
- 2000-12-15 GR GR20000100433A patent/GR1003658B/el unknown
- 2000-12-15 SK SK863-2002A patent/SK286752B6/sk not_active IP Right Cessation
- 2000-12-15 AT AT00403533T patent/ATE296622T1/de active
- 2000-12-15 ZA ZA200007548A patent/ZA200007548B/xx unknown
- 2000-12-15 WO PCT/FR2000/003546 patent/WO2001043747A1/fr active IP Right Grant
- 2000-12-15 IE IE20001017A patent/IE20001017A1/en not_active Application Discontinuation
- 2000-12-15 CZ CZ20022082A patent/CZ299461B6/cs not_active IP Right Cessation
- 2000-12-15 ES ES00403533.3T patent/ES2240033T5/es not_active Expired - Lifetime
- 2000-12-15 UA UA2002075914A patent/UA80087C2/uk unknown
- 2000-12-18 EA EA200001201A patent/EA008223B1/ru not_active IP Right Cessation
- 2000-12-18 BR BR0005915-3A patent/BR0005915A/pt not_active Application Discontinuation
- 2000-12-18 EA EA200501901A patent/EA200501901A1/ru unknown
-
2002
- 2002-07-16 BG BG106927A patent/BG65773B1/bg unknown
-
2007
- 2007-08-31 JP JP2007224959A patent/JP2007314578A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12121A (en) | Matrix tablet for prolonged release of trimetazidine after oral administration. | |
| EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
| PT88099B (pt) | Processo para a preparacao de composicoes farmaceuticas de acetaminofeno orais e de libertacao prolongada | |
| PT1945186E (pt) | Composições farmacêuticas orais sólidas para dosagem uma vez ao dia contendo pregabalina, um agente de formação de matriz e um agente de intumescimento | |
| AU2001260212A1 (en) | Composition | |
| WO1992003126A1 (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
| EP0284849A1 (en) | Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture | |
| KR20050035250A (ko) | 바이시파딘 포뮬레이션 | |
| PL191767B1 (pl) | Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków | |
| EP1104673A1 (en) | A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition | |
| HK1036937B (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
| WO2000013675A9 (en) | Methazolamide compositions and method of use | |
| HK1053601B (en) | Pharmaceutical composition for the controlled release of paracetamol |